سعر Survanta intratracheal 8ml vial 25 مجم phospholipids/مل 2026

Survanta beractant intratracheal suspension 200 mg phospholipids/8 mL (25 mg/mL) single-dose vial (AbbVie); natural bovine lung surfactant for respiratory distress syndrome in premature infants.

• Prevention and treatment (rescue) of respiratory distress syndrome (hyaline membrane disease) in premature infants.Population: Premature infantsDailyMed (NLM)

• Mostly dosing-procedure related: transient bradycardia (11.9% of doses), oxygen desaturation (9.8% of doses); <1%: tube reflux, pallor, vasoconstriction, hypotension, tube blockage, hypertension, hypo/hypercarbia, apnoea.International label, same product · DailyMed (NLM)

• None stated in the US label.International label, same product · DailyMed (NLM)

• Can rapidly affect oxygenation and lung compliance; use only in a highly supervised setting with clinicians experienced in intubation and ventilator management. Transient bradycardia and oxygen desaturation may occur during dosing: stop dosing, treat, and resume after stabilisation.International label, same product · DailyMed (NLM)
• Increased probability of post-treatment nosocomial sepsis was observed in controlled trials (not associated with increased mortality).International label, same product · DailyMed (NLM)